AXDX vs. OWLT, PRE, OMIC, OPTX, AATC, OPXS, CLIR, MSAI, DAIO, and BNGO
Should you be buying Accelerate Diagnostics stock or one of its competitors? The main competitors of Accelerate Diagnostics include Owlet (OWLT), Prenetics Global (PRE), Singular Genomics Systems (OMIC), Syntec Optics (OPTX), Autoscope Technologies (AATC), Optex Systems (OPXS), ClearSign Technologies (CLIR), MultiSensor AI (MSAI), Data I/O (DAIO), and Bionano Genomics (BNGO). These companies are all part of the "measuring and control equipment" industry.
Accelerate Diagnostics vs.
Owlet (NYSE:OWLT) and Accelerate Diagnostics (NASDAQ:AXDX) are both small-cap business services companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, community ranking and risk.
Accelerate Diagnostics received 348 more outperform votes than Owlet when rated by MarketBeat users. Likewise, 58.68% of users gave Accelerate Diagnostics an outperform vote while only 25.93% of users gave Owlet an outperform vote.
Owlet has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, Accelerate Diagnostics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.
In the previous week, Owlet and Owlet both had 5 articles in the media. Accelerate Diagnostics' average media sentiment score of 0.89 beat Owlet's score of 0.71 indicating that Accelerate Diagnostics is being referred to more favorably in the news media.
Owlet presently has a consensus target price of $7.75, suggesting a potential upside of 103.95%. Given Owlet's higher possible upside, equities research analysts plainly believe Owlet is more favorable than Accelerate Diagnostics.
Owlet has a net margin of -13.23% compared to Accelerate Diagnostics' net margin of -471.83%.
72.6% of Owlet shares are owned by institutional investors. Comparatively, 17.1% of Accelerate Diagnostics shares are owned by institutional investors. 67.1% of Owlet shares are owned by company insiders. Comparatively, 43.6% of Accelerate Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Owlet has higher revenue and earnings than Accelerate Diagnostics. Owlet is trading at a lower price-to-earnings ratio than Accelerate Diagnostics, indicating that it is currently the more affordable of the two stocks.
Summary
Owlet beats Accelerate Diagnostics on 10 of the 16 factors compared between the two stocks.
Get Accelerate Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Accelerate Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:AXDX) was last updated on 4/26/2025 by MarketBeat.com Staff
Buy AXDX Stock Free AXDX Stock Alerts